Simon Lichtiger, MD, built a career in gastroenterology spanning more than three decades, beginning with his medical degree from New York University School of Medicine after earning a bachelor’s degree at Yeshiva University. He served as an attending gastroenterologist at Mount Sinai Medical Center for nearly thirty years before joining Columbia University Medical Center in 2014 as professor of gastroenterology and director of the Inflammatory Bowel Disease Division, where he taught medical students, residents, and fellows while guiding research on Crohn’s disease and ulcerative colitis.
Lichtiger received the Leo Davidoff Society Certificate of Distinction and presented his work to the American Gastroenterological Association and the Falk Symposium in Germany. After 34 years in medicine, he shifted to teaching history at Ateres High School, though his contributions to gastroenterology, including the widely used activity index that measures ulcerative colitis severity, remain influential in clinical practice today.
The Lichtiger Score, formally known as the Lichtiger Colitis Activity Index (LCAI), is a clinical assessment tool used to measure disease activity in patients with ulcerative colitis (UC). Developed in the early 1990s, the Lichtiger Score was designed to provide a standardized and objective method for measuring ulcerative colitis activity. It is particularly useful in hospitalized patients with severe disease who do not respond adequately to steroid therapy. Since its introduction, it has been widely used in clinical research and inpatient care to evaluate treatment response and disease progression.
The scoring system is based on eight clinical factors that reflect a patient’s symptoms and overall condition. These factors include the number of daily bowel movements, the presence of nighttime diarrhea, visible blood in the stool, and the need for antidiarrheal medication. The other factors are fecal incontinence, abdominal pain, general well-being, and abdominal tenderness during examination. Each component is assigned a numerical value based on its severity, and the individual scores are summed to produce a total score.
The total Lichtiger Score ranges from 0 to 21. Lower scores generally indicate inactive or mild disease, while higher scores suggest more severe ulcerative colitis activity. A score of 3 or below is often associated with remission or mild disease. In contrast, scores of 10 or higher are considered indicative of severe disease activity.
Clinicians also use changes in the score to evaluate treatment effectiveness. A reduction of at least three points is commonly regarded as a meaningful clinical response. Remission is often defined as maintaining a score of 3 or less for at least two days in a row, remaining clinically stable, and not requiring surgery.
One of the primary advantages of the Lichtiger Score is its practicality. The assessment can be completed quickly and is suitable for daily monitoring in hospital settings. Because it focuses on symptoms that can change rapidly, it is particularly useful for tracking fluctuations in severe ulcerative colitis. This sensitivity makes it valuable in clinical trials where researchers need to measure how well a treatment is working over a short period.
Despite its usefulness, the Lichtiger Score has limitations. It has not undergone formal validation against endoscopic or histologic outcomes, meaning it does not directly measure the condition of intestinal tissues. Additionally, it may be less effective in distinguishing between levels of disease activity in patients with mild-to-moderate ulcerative colitis when compared with other assessment tools. The index also relies on a combination of objective findings and patient-reported symptoms, which can introduce variability, especially outside the hospital setting.
Researchers have suggested improving the Lichtiger colitis activity index by combining it with objective biomarkers such as fecal calprotectin (FC) and C-reactive protein (CRP). The index relies heavily on symptoms reported by patients. So, adding measurable indicators of inflammation may help provide a more accurate assessment of ulcerative colitis activity. Research has shown that FC is more closely associated with inflammation observed during endoscopic examinations than the Lichtiger score alone. As a result, combining symptom-based evaluations with biomarker data may enhance the ability to identify mucosal healing while reducing dependence on subjective symptom reporting. This approach also supports treat-to-target strategies by providing measurable information on inflammation to guide treatment decisions and adjustments.
Converting the Lichtiger index to a digital format could improve the monitoring of ulcerative colitis symptoms, particularly in telemedicine settings. Mobile health platforms already use comparable clinical scoring systems to help patients record symptoms, notify healthcare providers of potential concerns, and connect information with electronic health records. These features can reduce the need for frequent in-person appointments while supporting better symptom management and earlier identification of disease flare-ups. Applying the Lichtiger index within similar digital tools can allow patients to regularly track key symptoms, such as bowel movement frequency and abdominal pain. This information can help healthcare professionals monitor disease activity remotely and respond more quickly when treatment adjustments are needed.
Although the Lichtiger Score is an important tool for evaluating ulcerative colitis activity, it is not intended to serve as a standalone diagnostic method. Instead, it functions as part of a broader clinical assessment, helping healthcare professionals monitor disease severity, evaluate treatment response, and make informed decisions about patient care. Its continued use highlights its value in the management of acute and severe ulcerative colitis.
About Simon Lichtiger
Simon Lichtiger, MD, spent more than three decades in gastroenterology, including nearly thirty years as an attending gastroenterologist at Mount Sinai Medical Center and a later role as professor of gastroenterology and director of the Inflammatory Bowel Disease Division at Columbia University Medical Center. He earned recognition from the American Gastroenterological Association and the Falk Symposium for his contributions to ulcerative colitis research. After 34 years in medicine, Lichtiger transitioned to teaching history at Ateres High School.